{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,30]],"date-time":"2026-01-30T03:05:27Z","timestamp":1769742327775,"version":"3.49.0"},"reference-count":15,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.es","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Reumatolog\u00eda Cl\u00ednica (English Edition)"],"published-print":{"date-parts":[[2021,10]]},"DOI":"10.1016\/j.reumae.2020.06.003","type":"journal-article","created":{"date-parts":[[2020,6,11]],"date-time":"2020-06-11T22:56:49Z","timestamp":1591916209000},"page":"437-439","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Psoriasis induced by biological therapy"],"prefix":"10.1016","volume":"17","author":[{"given":"Lydia","family":"Montolio Chiva","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"\u00c0ngels","family":"Mart\u00ednez Ferrer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Almudena","family":"Mateu Puchades","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cristina","family":"Campos Fern\u00e1ndez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Javier","family":"Narv\u00e1ez Garcia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Juan Jos\u00e9","family":"Alegre Sancho","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.reumae.2020.06.003_bib0080","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.reuma.2012.04.007","article-title":"Lesiones cut\u00e1neas y terapia biol\u00f3gica con antagonistas del factor de necrosis tumoral","volume":"9","author":"Hern\u00e1ndez","year":"2013","journal-title":"Reumatol Clin"},{"key":"10.1016\/j.reumae.2020.06.003_bib0085","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1067\/mjd.2000.105948","article-title":"Treatment with anti-tumor necrosis factor \u03b1 (TNF-\u03b1) monoclonal antibody dramatically decreases the clinical activity of psoriasis lesions","volume":"42","author":"Oh","year":"2000","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.reumae.2020.06.003_bib0090","series-title":"Current problems in dermatology","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1159\/000479475","article-title":"Paradoxical reactions: anti-tumor necrosis factor alpha agents, ustekinumab, secukinumab, ixekizumab, and others","author":"Puig","year":"2018"},{"key":"10.1016\/j.reumae.2020.06.003_bib0095","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1001\/archderm.143.2.223","article-title":"Psoriasis and pustular dermatitis triggered by TNF\u03b1 inhibitors in patients with rheumatologic conditions","volume":"143","author":"De Gannes","year":"2007","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.reumae.2020.06.003_bib0100","first-page":"1029","article-title":"Dermatological complications of therapy with biologics in inflammatory autoinmmune diseases","volume":"17","author":"Sondermann","year":"2019","journal-title":"J Disch Dermatol Ges"},{"key":"10.1016\/j.reumae.2020.06.003_bib0105","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1016\/j.semarthrit.2010.04.003","article-title":"Psoriatic skin lesions induced by tumor necrosis factor antagonist therapy: clinical features and possible immunopathogenesis","volume":"40","author":"Collamer","year":"2010","journal-title":"Semin Arthritis Rheum"},{"key":"10.1016\/j.reumae.2020.06.003_bib0110","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1016\/j.jaad.2008.09.032","article-title":"Lichen planus-like eruptions: an emerging side effect of tumor necrosis factor-\u03b1 antagonists","volume":"61","author":"Asarch","year":"2009","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.reumae.2020.06.003_bib0115","doi-asserted-by":"crossref","first-page":"880","DOI":"10.1111\/apt.13352","article-title":"Paradoxical psoriasis in a large cohort of patients with inflammatory bowel disease receiving treatment with anti-TNF alpha: 5-year follow-up study","volume":"42","author":"Pugliese","year":"2015","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.reumae.2020.06.003_bib0120","first-page":"169","article-title":"Psoriasis induced by anti-tumor necrosis factor alpha agents: a comprehensive review of the literature","volume":"24","author":"Ciccarelli","year":"2016","journal-title":"ACTA Dermatovenerol Croat"},{"key":"10.1016\/j.reumae.2020.06.003_bib0125","doi-asserted-by":"crossref","first-page":"2927","DOI":"10.1007\/s00296-012-2581-3","article-title":"Induced psoriasis after rituximab therapy for rheumatoid arthritis: a case report and review of the literature","volume":"33","author":"Guidelli","year":"2013","journal-title":"Rheumatol Int"},{"key":"10.1016\/j.reumae.2020.06.003_bib0130","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1159\/000437415","article-title":"Psoriasiform drug eruption caused by abatacept: inmunohistochemical investigation of STAT signaling","volume":"7","author":"Tanita","year":"2015","journal-title":"Case Rep Dermatol"},{"key":"10.1016\/j.reumae.2020.06.003_bib0135","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1016\/j.revmed.2014.01.007","article-title":"R\u00e9actions cutan\u00e9es paradoxales sous traitement par tocilizumab","volume":"35","author":"Sparsa","year":"2014","journal-title":"Rev M\u00e9decine Interne"},{"key":"10.1016\/j.reumae.2020.06.003_bib0140","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1111\/1346-8138.13803","article-title":"Exacerbation of infliximab-induced paradoxical psoriasis after ustekinumab therapy","volume":"45","author":"Suh","year":"2018","journal-title":"J Dermatol"},{"key":"10.1016\/j.reumae.2020.06.003_bib0145","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1159\/000339864","article-title":"Ustekinumab treatment of TNF antagonist-induced paradoxical psoriasis flare in a patient with psoriatic arthritis: case report and review","volume":"225","author":"Puig","year":"2012","journal-title":"Dermatol Basel Switz"},{"key":"10.1016\/j.reumae.2020.06.003_bib0150","doi-asserted-by":"crossref","first-page":"1521","DOI":"10.1111\/ijd.14072","article-title":"Clinical management of anti-TNF-alpha-induced psoriasis or psoriasiform lesions in inflammatory bowel disease patients: a systematic review","volume":"57","author":"Melo","year":"2018","journal-title":"Int J Dermatol"}],"container-title":["Reumatolog\u00eda Cl\u00ednica (English Edition)"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2173574320300678?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2173574320300678?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T02:59:41Z","timestamp":1761879581000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2173574320300678"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,10]]},"references-count":15,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2021,10]]}},"alternative-id":["S2173574320300678"],"URL":"https:\/\/doi.org\/10.1016\/j.reumae.2020.06.003","relation":{},"ISSN":["2173-5743"],"issn-type":[{"value":"2173-5743","type":"print"}],"subject":[],"published":{"date-parts":[[2021,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Psoriasis induced by biological therapy","name":"articletitle","label":"Article Title"},{"value":"Reumatolog\u00eda Cl\u00ednica (English Edition)","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.reumae.2020.06.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"https:\/\/doi.org\/10.1016\/j.reuma.2019.12.005","name":"associatedlink","label":"CrossRef DOI link to the associated document"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier Espa\u00f1a, S.L.U. and Sociedad Espa\u00f1ola de Reumatolog\u00eda y Colegio Mexicano de Reumatolog\u00eda. All rights reserved.","name":"copyright","label":"Copyright"}]}}